Transthyretin Stabilizers Market size is anticipated to reach USD 29 Billion by the end of 2036, expanding around 9% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of transthyretin stabilizers was over USD 13 Billion. The market is witnessing a robust surge, driven primarily by the escalating prevalence of Transthyretin Amyloidosis (ATTR). ATTR, a rare and debilitating disease, is characterized by the abnormal accumulation of transthyretin protein, leading to organ dysfunction and a myriad of clinical manifestations. As the incidence of ATTR rises globally, the demand for effective therapeutic interventions, including transthyretin stabilizers, is experiencing unprecedented growth. According to a recent epidemiological study, the global prevalence of ATTR has exhibited a significant increase over the past decade. In 2010, the estimated prevalence of ATTR was 10 cases per 100,000 population, and by 2020, this figure surged to 25 cases per 100,000 population. This compelling statistic underscores the urgent need for therapeutic interventions, driving significant growth in the market.
Transthyretin stabilizers are drugs designed to stabilize the transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils. By stabilizing the protein, these drugs aim to slow down or halt the progression of ATTR and alleviate associated symptoms. Several transthyretin stabilizers were under development by various pharmaceutical companies. Among them, tafamidis was one of the first drugs to receive regulatory approval for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in some regions.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
9% |
|
Base Year Market Size (2023) |
USD 13 Billion |
|
Forecast Year Market Size (2036) |
USD 29 Billion |
|
Regional Scope |
|
Type (Tafamidis, Inotersen)
The inotersen segment in the transthyretin stabilizers market is estimated to gain the largest revenue share of 61% in the year 2036. Ongoing efforts to expand Inotersen's label to encompass a broader patient population contribute to its segmental growth. Label expansions based on clinical trial results provide an avenue for reaching a larger pool of ATTR patients. The successful expansion of Inotersen's label to include specific genotypes previously excluded was supported by a Phase 3 study, resulting in a 25% increase in eligible patients for Inotersen therapy. Expanding patient access through label expansions not only broadens the market reach of Inotersen but also addresses the unmet needs of a more diverse patient population, fostering sustained growth in its segment. Inotersen's growth in the market is further propelled by its demonstrated efficacy in polyneuropathy and cardiomyopathy management, the convenience of subcutaneous administration, and strategic efforts to expand patient access through label expansions.
End User (Hospitals, Clinics, Home Healthcare)
The hospitals segment in the transthyretin stabilizers market is expected to garner a significant share in the year 2036. Hospitals often serve as hubs for clinical research and trials, fostering innovation and advancing the understanding of transthyretin amyloidosis. The integration of research activities within hospital settings contributes to the development of new therapeutic interventions. The integration of research and participation in clinical trials within hospitals not only positions them as centers of medical advancement but also attracts patients seeking access to cutting-edge treatments, contributing to the growth of the Hospitals segment. The growth of the hospitals segment in the market is further driven by a multidisciplinary approach, access to advanced diagnostic technologies, comprehensive patient monitoring, care coordination, and the integration of research and clinical trials.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
APAC Market Forecast
The transthyretin stabilizers market in the Asia Pacific region is projected to hold the largest market share of 40% by the end of 2036. The adoption of telehealth and remote patient monitoring solutions is contributing to the growth of the market in the Asia Pacific region. These technological advancements improve patient access to healthcare and facilitate remote management of transthyretin amyloidosis. Telehealth adoption in the Asia Pacific region increased by 40% in the last two years, with a notable rise in remote consultations for rare disease management. The integration of telehealth technologies enhances patient engagement and provides a platform for effective monitoring and management of transthyretin amyloidosis, thereby supporting the growth of the market. The market in the Asia Pacific region is further propelled by increasing disease awareness, strategic collaborations, government support, the aging population, and the adoption of innovative healthcare technologies.
North American Market Statistics
The transthyretin stabilizers market in the North America region is projected to hold the second largest share during the forecast period. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The extensive research and development ecosystem in North America not only foster the discovery of new transthyretin stabilizers but also positions the region as a key contributor to global therapeutic innovation. The escalating prevalence of transthyretin amyloidosis in North America is a fundamental driver for the market. A growing understanding of the disease's spectrum and improved diagnostic capabilities contribute to a higher number of identified cases.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?